To the full analysis
Enanta Pharmaceuticals stock: growth
ENTAEnanta Pharmaceuticals reported $65.32M in revenue for fiscal 2025, down 3.4% on the prior year, down 11.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
7.3%
per year from 2010 to 2025, per share 3.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2010 | |
|---|---|---|---|
| Revenue | −11.8% | −8.6% | 7.3% |
| Revenue per share | −13.0% | −9.8% | 3.7% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2010 | $22.76M | $7.9M | −$10.21M |
| 2011 | $41.88M | $23.31M | $23.57M |
| 2012 | $41.71M | $21.4M | $22.37M |
| 2013 | $32.05M | $9.63M | $10.05M |
| 2014 | $47.74M | $34.44M | $19.15M |
| 2015 | $160.88M | $78.99M | $74.34M |
| 2016 | $88.27M | $21.67M | $31.07M |
| 2017 | $102.81M | $17.71M | $50.15M |
| 2018 | $206.63M | $71.96M | $26.24M |
| 2019 | $205.2M | $46.38M | $66M |
| 2020 | $122.47M | −$36.17M | $5.64M |
| 2021 | $97.07M | −$79M | −$70.75M |
| 2022 | $86.16M | −$121.76M | −$86.91M |
| 2023 | $79.2M | −$133.82M | −$112.21M |
| 2024 | $67.64M | −$116.05M | −$96.71M |
| 2025 | $65.32M | −$81.89M | −$32.17M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Sep 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2020)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.